~~<i id='21771E49DE'><strike id='21771E49DE'><tt id='21771E49DE'><pre id='21771E49DE'></pre></tt></strike></i>~~

Home» comprehensive» comprehensive

comprehensive

author：entertainment 2025-10-06 13:23:22 Page View：16323

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： What the US credit downgrade means for the economy, your finances
Next article： United colonoscopy coverage change 'may cost lives,' doctors say

leisure time

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

WASHINGTON--TheSupremeCourtwillreviewarulingstrikingdownadomesticviolencefederalgunban.

Vertex non

BillSikes/APVertexPharmaceuticalshasspentdecadestryingtodevelopmoleculesthatreducepainsafelyandpoten

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

STAT Summit: Ending the crisis of Black deaths in the U.S.

MonicaMcLemore,aprofessorandinterimassociatedeanforequity,diversity,andinclusionattheUniversityofWas